Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Next generation sequencing analysis of transcriptomes at different timepoints after CBL0137 treatment in SU-DHL-4, Raji and Jeko cell lines

ABSTRACT: To understand the mechanisms of CBL0137 in B-NHL therapy, gene expression changes of SU-DHL-4, Raji and Jeko cell lines after CBL0137 treatment were analyzed by RNA-seq

ORGANISM(S): Homo sapiens

PROVIDER: GSE208679 | GEO | 2023/02/07

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Next generation sequencing analysis of transcriptomes at different timepoints after CBL0137 treatment in SU-DHL-4, Raji and Jeko cell lines

Project description:Next generation sequencing analysis of transcriptomes at different timepoints after CBL0137 treatment in SU-DHL-4, Raji and Jeko cell lines

| PRJNA860600 | ENA

Proteomes of chromatin fractions derived from SU-DHL-5 cells

Project description:SU-DHL-5 cells display limited expression of the SUMO isopeptidase SENP6. In this experiment, the chromatin associated fraction of SU-DHL-5 cells was analysed by mass spectrometry. SU-DHL-5 cells were either stably transfected with an empty vector or with a SENP6 expression construct. Changes in protein levels were compared between these two cell lines in triplicate experiments.

2022-02-17 | PXD027355 | Pride

Genes expression of SU-DHL-2 cells treated with IL-17A

Project description:To further figure out the molecular mechanisms of IL-17A-mediated DLBCL cells growth, we used the Whole Human Genome Oligo Microarray (4×44K, Agilent Technologies) to identify genes expression. Six samples of SU-DHL-2 cells (2×10^6 cells/ml) co-cultured with or without IL-17A (200pg/ml) for 72hr in vivo. Three samples of SU-DHL-2 cells were all co-cultured with IL-17A , other three samples of SU-DHL-2 cells without IL-17A treatment were used as controls. Then, all these six samples of SU-DHL-2 cells were measured by microarray.

2018-06-16 | GSE115855 | GEO

ChIA-PET from SU-DHL-2 (ENCSR128RPG)

Project description:RAD21 ChIA-PET in human SU-DHL-2 cells For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf

2019-03-03 | GSE127019 | GEO

ChIA-PET from SU-DHL-4 (ENCSR658RQQ)

Project description:RAD21 ChIA-PET in human SU-DHL-4 cells For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf

2019-03-03 | GSE127039 | GEO

Effect of CBL0137 on DIPG cells

Project description:Diffuse intrinsic pontine glioma (DIPG) is an aggressive and incurable childhood brain tumor for which new treatments are needed. A high throughput drug screen of 3600 pharmaceutical compounds found that anti-malarials, including quinacrine had potent activity against DIPG neurospheres. CBL0137 is a novel anti-cancer compound developed from quinacrine, which targets Facilitates Chromatin Transcription (FACT), a chromatin remodelling complex involved in transcription, replication, and DNA repair. We have found that CBL0137 displays profound cytotoxic activity against a panel of patient derived DIPG cultures, inhibiting cell proliferation and clonogenic potential, restoring tumor suppressor TP53 and Rb activity and inducing cell death through induction of apoptosis. Moreover, in an orthotopic model of DIPG, treatment with CBL0137 significantly extended animal survival. Histone mutations leading to the loss of histone trimethylation result in epigenetic dysregulation driving DIPG tumorigenesis. Treatment with CBL0137 targets this epigenetic defect, restoring both histone H3.3 acetylation and trimethylation and leading to tumor cell death. Combined epigenetic treatment with the histone deacetylase (HDAC) inhibitor panobinostat led to inhibition of the Rb/E2F1 pathway, and increased the enzymatic activity of enhancer of zeste homolog 2 (EZH2), leading to the restoration of H3K27 trimethylation. This combination therapy had synergistic activity against DIPG neurospheres with induction of apoptosis. Consistent with the in vitro results, the combination of CBL0137 and panobinostat significantly prolonged the survival of mice bearing DIPG orthografts suggesting a potential treatment strategy for DIPG.

2021-03-07 | GSE153883 | GEO

Effect of bryostatin-1 on gene expression profile of Raji cells

Project description:To investigate bryostain's effect on Raji , we performed a whole-transcriptome RNA sequencing experiment for Raji cells treated with Bryostatin and established differntial expression profile comparing to raji treated with DMSO.

2022-08-19 | GSE211351 | GEO

Combination of CBL0137 and Panobinostat in DIPG

2021-02-12 | GSE153441 | GEO

ena-DATASET-DKFZ-IBIOS-17-08-2015-09:13:01:216-19 - samples

Project description:PAR-CLIP was performed on the Argonaute-2 protein (AGO2) in four lymphoma cell lines: Namalwa Raji SU-DHL-4 SU-DHL-6

| EGAD00001001468 | EGA

Genes expression of SU-DHL-2 cells treated with IL-17A

Project description:Genes expression of SU-DHL-2 cells treated with IL-17A

| PRJNA476315 | ENA